Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 April 2025 | Story Reuben Maeko | Photo Supplied
Dr Mutshidzi Mulondo
Dr Mutshidzi Mulondo, UFS academic in the Division of Public Health within the Faculty of Health Sciences at the UFS.

Dr Mutshidzi Mulondo, an academic in the Division of Public Health within the Faculty of Health Sciences at the University of the Free State (UFS), will make history when she becomes the first academic from the institution to be inaugurated into the Global Young Academy (GYA).

Dr Mulondo is one of two South Africans that are part of the 2025 cohort of incoming members who will be inaugurated to the sought-after prestigious Academy in Hyderabad, India. The other South African is Dr Mbuzeleni Hlongwa, a Senior Research Specialist at the Human Sciences Research Council.

The Global Young Academy is a network institution of the United Nations Scientific Advisory Board which allows young scientists from around the world to collaborate on research, set the global agenda, and contribute to global policies. The GYA develops, connects and mobilises young talent from six continents, and empowers young researchers to lead international, interdisciplinary and intergenerational dialogue and contribute to societal challenges. The GYA aims to elevate the voice of young scientists in evidence-informed and inclusive global, regional and national decision making.

The membership is comprised of passionate young scientists, typically who obtained their PhD degrees three to 10 years earlier, are between 30 to 40 years of age, and in the early stages of their independent academic careers. Members are selected for their scientific excellence and commitment to engage with society, and serve five-year terms.

 

Global Young Academy

“I feel honoured to be selected. The selection further cements the ingenuity of young African scientists and our ability to shape the global agenda. It allows us to envision a future together which leans towards empathy, kindness and unity,” said Dr Mulondo.

The Academy hopes to bridge the gap between established and new academics as well the gap between academics from the Global North and Global South. Further positioning academics from the south for interdisciplinary collaboration and publication in high impact journals to address complex and emerging challenges such as public health issues. The Academy selects young academics who display contribution to research, dedication to serving society and the ability to make an impact on the Academy’s community.

 

Aspirations in the academy

The recognition is testament that Africa is still producing globally competitive academics. This achievement is even better as it comes during the G20 presidency when Africa is showing what the developing world can produce. Coincidentally, Dr Mulondo, was one of the invited speakers at the G20 Research & Innovation Working Group, joining other selected young academics.

According to Dr Mulondo, who won the Zenith Global Health Award under the category ‘Mental Health and Well-being’ last year and was first runner-up in the category Emerging Leader at the South African Health Excellence Award. Academics from Africa have a responsibility to contribute to the development of the continent through evidence-based advice and solutions to policymakers. This membership allows young academics to stay in touch with global scientific trends and shifts in order to be better informed about resolving some of humanity’s most pressing crises.

She hopes to continue to advance public health strategies that prioritise mental health and health equity. With geopolitical complexities, climate changes and technological advancements shaping our future, the Academy allows for voices from the Global South to contribute to global policies and influence global policy decisions. “As a mentor and supervisor of master’s and PhD students in Public Health, I hope to contribute to ushering in a new generation of well-rounded public health researchers who are societally engaged.”

Prof Anthea Rhoda, UFS Deputy Vice-Chancellor: Academic, congratulated Dr Mulondo, saying the UFS is extremely proud of her. “Being selected as one of two South African scholars to the Global Young Academy demonstrates her dedication as a public health scholar passionate about making a difference in the health and well-being of society. Well done, on this great achievement.”

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept